A clinical trial of voriconazole for deep-seated mycosis. An Uncontrolled Multicenter Study

Japanese Journal of Chemotherapy

Volumn 53, Issue SUPPL. 2, 2005, Pages 32-50

  Niki, Yoshihito ^a   Yoshida, Minoru ^b   Shimada, Kaoru ^c   Kohno, Shigeru ^d   Masaoka, Tohru ^e   Yamaguchi, Hideyo ^f   Aikawa, Naoki ^g   Mori, Takeshi ^h   Andoh, Masahiro ⁱ   Nakata, Koichiro ^j   Kudo, Koichiro ^k   Arai, Yukihiro ^l   Takeuchi, Jin ^m   Mizoguchi, Hideaki ⁿ   Uchida, Kou ^o   Mikamo, Hiroshige ^p   Yanagihara, Katsunori ^d   Miyazaki, Yoshitsugu ^d   Ikematsu, Hideyuki ^q   Matsuoka, Rokuro ^r   Yoshida, Koichiro ^a   Miwa, Akiyoshi ^s   Oka, Shinichi ^s   Taniwaki, Masafumi ^t   Watanabe, Masato ^u   Motojima, Shinji ^v   Konishi, Mitsuru ^w   Okamoto, Shinichiro ^x   Matsuda, Takahide ^y   Murakami, Takehisa ^b   Nakashima, Yukata ^b   Hotta, Tomomitsu ^z   Ito, Yoshikazu ^aa   Emi, Nobuhiko ^ab   Mutoh, Yoshitomo ^j   Nishimura, Miki ^ac   Kimura, Kazuhiro ^o   Mizutani, Tetsu ^ad   Usuki, Kensuke ^ae   Takamatsu, Yasushi ^af   Kadota, Junichi ^ag   Miura, Osamu ^ah   Sakamaki, Hisashi ^ai   Kami, Masahiro ^aj   Yamada, Osamu ^a   Wada, Hideho ^ak   Usui, Noriko ^al   Nagai, Masami ^am   Takesue, Yoshio ^an   Tanaka, Minoru ^ao   Kimura, Fumihiko ^ap   Kurashima, Atsuyuki ^aq   Abe, Masahiro ^ar   Igari, Hidetoshi ^ac   Takahashi, Takayuki ^as   more..

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Tokyo Senbai Hospital   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f TEIKYO UNIVERSITY   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ Tsuboi Hospital   (Japan)

^j TORANOMON HOSPITAL   (Japan)

^k National Medical Center Hospital   (Japan)

^l DOKKYO MEDICAL UNIVERSITY   (Japan)

^m NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^o TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q Hara Doi Hospital   (Japan)

^r Showa General Hospital   (Japan)

^s NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^t KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^u MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^v Kameda General Hospital   (Japan)

^w NARA MEDICAL UNIVERSITY   (Japan)

^x KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^z TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^aa TOKYO MEDICAL UNIVERSITY   (Japan)

^ab NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ac CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ad Kitano Hospital   (Japan)

^ae Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^af FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ag OITA UNIVERSITY   (Japan)

^ah TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^ai TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^aj NATIONAL CANCER CENTER HOSPITAL   (Japan)

^ak Division of Hematology   (Japan)

^al JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^am KAGAWA UNIVERSITY   (Japan)

^an HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^ao JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^ap NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^aq TOKYO NATIONAL HOSPITAL   (Japan)

^ar UNIVERSITY OF TOKUSHIMA   (Japan)

^as KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

more..

Author keywords

Aspergillosis; Candidiasis; Cryptococcosis; Triazole antifungal agent; Voriconazole

Indexed keywords

AMPHOTERICIN B; CYTOCHROME P450 2C19; GAMMA GLUTAMYLTRANSFERASE; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BACKACHE; BLOOD TOXICITY; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONSTIPATION; COUGHING; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; ERADICATION THERAPY; ERYTHEMA; FEMALE; FEVER; FUNGAL STRAIN; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMOPTYSIS; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INSOMNIA; LIVER TOXICITY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PHOTOPHOBIA; PNEUMONIA; RETINA HEMORRHAGE; SALVAGE THERAPY; SEPSIS; SEROLOGY; THORAX PAIN; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING;

EID: 29644436952     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Epinel-Ingroff A: In vitro activity of the new triazole voriconazole (UK-109, 494) against opportunistic filamentous and dimorphic fungi and common and emerging pathogens. J Clin Mcrobiol 36: 198-202, 1998
2. Johnson L B, Kauffman C A: Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36: 630-637, 2003
3. Maesaki S, Iwakawa J, Higashiyama Y, et al: Antifungal activity of a new triazole, voriconazole (UK-109, 496), against clinical isolates of Aspergillus spp.. J Infect Chemother 6: 101-103, 2000
4. Sanati H, Belanger P, Fratti B, et al: A new triazole, voriconazole (UK-109, 496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41: 2492-2496, 1997
5. Denning D W, Ribaud P, Milpied N, et al: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34: 563-571, 2002
6. Ally R, Schürmann D, Kreisel W, et al: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33: 1447-1454, 2001
7. Herbrecht P, Denning D W, Patterson T F, et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415, 2002
8. Perfect J R, Marr K A, Walsh T J, et al: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36: 1122-1131, 2003
9. Japanese source. 59 (Suppl 7): 154-161, 2001
10. Xie H G, Stein C M, Kim R B, et al: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9: 539-549, 1999
11. Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60: 661-666, 1996
12. Marinac J S, Balian J D, Foxworth J W, et al: Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 60: 138-144, 1996
13. Xie H G: Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population. Life Sci 66: PL175-181, 2000
14. Desta Z, Zhao X, Shin J G, et al: Clinical Significance of the Cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913-958, 2002